Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors during the central anxious process, conolidine modulates alternate molecular targets. A Science Advancements research discovered that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availa... https://lyndond318wya9.glifeblog.com/profile